Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Oct 11:10:546.
doi: 10.1186/1471-2407-10-546.

Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC

Alexandra D Jensen  1 , Anna Nikoghosyan, Christine Windemuth-Kieselbach, Jürgen Debus, Marc W Münter
Affiliations
Clinical Trial

Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC

Alexandra D Jensen et al. BMC Cancer. .

Abstract

Background: Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild side-effects.

Methods/design: The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).

Discussion: The primary objective of COSMIC is to evaluate toxicity and feasibility of the proposed treatment in all salivary gland malignancies.

Trial registration: Clinical trial identifier NCT 01154270.

Trial registration: ClinicalTrials.gov NCT01154270.

PubMed Disclaimer

Figures

Figure 1
Figure 1
trial flow-chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8(3):177–84. doi: 10.1002/hed.2890080309. - DOI - PubMed
    1. Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK. et al.Local-regional recurrence after surgery without postoperative irradiation for carciomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007;67:982–987. - PubMed
    1. Gurney TA, Eisele DW, Weinberg V, Shin E, Lee N. Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope. 2005;115(7):1278–82. doi: 10.1097/01.MLG.0000165381.64157.AD. - DOI - PubMed
    1. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004;26(2):154–62. doi: 10.1002/hed.10380. - DOI - PubMed
    1. Chen AM, Bucci MK, Weinberg V, Garcia J, Quivey JM, Schechter NR. et al.Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys. 2006;66(1):152–9. - PubMed

Publication types

Associated data